Navigation Links
Tapestry Reports Second Quarter 2007 Results
Date:8/19/2007

Results Reflect Continued Investment in Clinical Development of TPI 287

BOULDER, Colo., Aug. 9 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH) announced today financial results for the second quarter ended June 27, 2007.

The net loss for the second quarter of 2007 was $6.2 million, or $0.37 per share. This compares to a net loss for the second quarter of 2006 of $4.2 million, or $0.28 per share. Included in the net loss for the second quarter of 2007 and 2006 is non-cash equity compensation expense totaling $893,000 and $1.3 million, respectively.

The net loss for the six-months ended June 27, 2007 was $10.6 million, or $0.64 per share. This compares to a net loss for the six-months ended June 28, 2006 of $8.6 million, or $0.92 per share. Included in the net loss for the six-months ended June 27, 2007 and June 28, 2006 is non-cash equity compensation expense totaling $1.7 million and $1.9 million, respectively.

As of June 27, 2007, Tapestry had $14.4 million in cash, cash equivalents, and short-term investments.

"The first half of 2007 has been an extremely exciting time at the company, as we initiated our first Phase 2 trial for TPI 287, in hormone refractory prostate cancer, and shared promising preclinical and Phase I clinical data at AACR and ASCO," commented Leonard Shaykin, Chairman and CEO. "We plan to build on this momentum in the second half of the year as we initiate our second and third Phase 2 trials in pancreatic cancer and in glioblastoma multiforme and our first oral Phase 1b/2 PK study in man. By early 2008, we expect to have preliminary results from the first arm of our Phase 2 trial in hormone refractory prostate cancer and begin an additional expl
'/>"/>

SOURCE Tapestry Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6

Related medicine technology :

1. Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... development and sale of patented biopharmaceutical medicine, modernized traditional ... (API) today announced the business and development progress at ... 1. Following the September 2014 JCM application (No. 51268) ...
(Date:1/22/2015)... Inc. (NASDAQ: UPI ), a medical device company ... treat voiding dysfunctions, today reported financial results for the ... Global revenue for the Company,s Urgent ®  PC Neuromodulation ... revenue record, as compared to $3.9 million in the ...
(Date:1/22/2015)... Calif. , Jan. 22, 2015  Amgen (NASDAQ: AMGN ... full year 2014 financial results on Tuesday, Jan. 27, 2015, after ... followed by a conference call with the investment community at 2 ... Robert A. Bradway , chairman and chief executive officer, and other ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... Company Focused on IND-Enabling Work with Protein Therapeutics that ... Modulate Alternative Pathway of Complement System, CAMBRIDGE, ... has initiated a corporate growth plan with the,appointment of ... of its headquarters in Cambridge, Mass. Dr. Celniker succeeds,Woodruff ...
... Nonin Medical, a leading innovator,of physiological monitoring solutions ... testing phase with its breakthrough technology to measure,regional ... is the continuous monitoring of the regional blood ... testing data and outcomes from an ongoing clinical ...
Cached Medicine Technology:Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2
(Date:1/22/2015)... 2015 Four years since the release of their ... with the marriage of Avasa & Matthew Love – the duo ... scheduled for release through White Swan Records on February 24, 2015. ... a sacred path available to all of us to walk out ...
(Date:1/22/2015)... Mass. (PRWEB) January 22, 2015 EBSCO ... (AMA) are expanding their relationship in an effort to ... around the world. While EBSCO has long made AMA journals ... a sales agent for The JAMA Network. , ...
(Date:1/22/2015)... 2015 JJsHouse.com is a famous dress online ... business announces its latest collection of wedding dresses , ... important issue is the wedding dress on your big day; ... woman’s life. Every bride wants to find the most suitable ...
(Date:1/22/2015)... January 22, 2015 Lower-Auto-Insurance.com has released a new ... in a car for reducing the costs of an auto ... also be able to get lower prices for their vehicle insurance ... important role in determining policy costs. Because of this, drivers ...
(Date:1/22/2015)... State Forestry Institute of Mecklenburg-Vorpommern in ... support from GEOSYSTEMS, a dedicated Hexagon Geospatial and Intergraph ... Hexagon Geospatial’s ERDAS APOLLO for cataloging, managing, ... point clouds and documents. This effort will enable the ...
Breaking Medicine News(10 mins):Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... State University researchers have now developed a new medical ... stem cells to be grown in sufficient quantities to ... tissues. This overcomes the currently involved technical difficulties in ... called a perfusion bioreactor is designed to mimic conditions ...
... Minister Dr Anbumani Ramadoss, in an attempt to tackle ... for Beijing to approach China, the only country where ... The heavy toll of valuable human lives in Uttar ... health Minister., ,The health minister has also planned ...
... the right of teenage under-16s girl to have abortion without ... brought by Ms Axon as one of her daughter is ... told the court that parents are mostly out dated and ... the views of their children’s. Law has been introduced which ...
... a practical and cost effective new way to combat the ... genetically modified bacteria living in the human body to produce ... transmission occurs on the surfaces of the gut and reproductive ... ,The researchers have successfully modified one of these ...
... health officials are closely watching the developments in a ... made reappearance after vaccine-related exposure among its members. ... through visitors from the United States. Health officials are ... but it is thought to be in close vicinity ...
... is on track to roll-out a nationwide screening programme ... infertility in both sexes//. ,So far nearly 80,000 ... difficult to detect but is easy to cure, following ... Programme (NCSP). ,There has been a heightened concern ...
Cached Medicine News:Health News:Perfusion bioreactor could enhance stem cell research and application in the future 2Health News:Indian Government Keen On JE Vaccine Supply And Patenting Of Indian Medicine Formulations 2Health News:Genetically modified bacteria to combat HIV 2Health News:UK Govt Says On Course For National Chlamydia Screening 2
Inquire...
... The advanced design of the ... its sleek, modern configuration, now ... color to complement any office ... designed to integrate into existing ...
The VPAP III ST is a complete system solution for SDB, providing comfortable and effective bilevel treatment with additional treatment modes. The VPAP III ST is an effective business solution for cli...
The GoodKnight® 425 Bi-Level® device is suitable for travel and includes features such as automatic altitude compensation, optional cigarette lighter adapter and portable battery pack...
Medicine Products: